

CORRECTED
VERSION*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/00, 31/60	A2	(11) International Publication Number: WO 98/20864 (43) International Publication Date: 22 May 1998 (22.05.98)
<p>(21) International Application Number: PCT/EP97/06323</p> <p>(22) International Filing Date: 13 November 1997 (13.11.97)</p> <p>(30) Priority Data: MI96A002356 13 November 1996 (13.11.96) IT</p> <p>(71) Applicant (for all designated States except US): UNIVERSITA' DEGLI STUDI DI BRESCIA - DIPARTIMENTO DI SCIENZE BIOMEDICHE [IT/IT]; Piazza del Mercato, 15, I-25121 Brescia (IT).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): GRILLI, Mariagrazia [IT/IT]; Dipartimento di Scienze Biomediche, Via Valsabbina, 19, I-25123 Brescia (IT). PIZZI, Marina [IT/IT]; Dipartimento di Scienze Biomediche, Via Valsabbina, 19, I-25123 Brescia (IT). MEMO, Maurizio [IT/IT]; Dipartimento di Scienze Biomediche, Via Valsabbina, 19, I-25123 Brescia (IT). SPANO, Pierfranco [IT/IT]; Dipartimento di Scienze Biomediche, Via Valsabbina, 19, I-25123 Brescia (IT).</p> <p>(74) Agent: MINOJA, Fabrizio; Blanchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).</p>		<p>(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: USE OF SELECTED NON-STEROIDAL ANTIINFLAMMATORY COMPOUNDS FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES</p>		
<p>(57) Abstract</p> <p>The present invention relates to the use of non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases such as Alzheimer' and Parkinson's disease.</p>		

BEST AVAILABLE COPY

* (Referred to in PCT Gazette No. 34/1998, Section II)

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF SELECTED NON-STEROIDAL ANTIINFLAMMATORY COMPOUNDS FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES

The present invention relates to the use of selected non-steroidal antinflammatory compounds for the prevention and the treatment of glutamate receptor-mediated neuronal damages, such compounds being selected from:

(a) the group of compounds deriving from acetylsalicylic acid of the following formula (I)



wherein:

15 A is H; (C₁-C₄)-alkyl, optionally substituted with a carboxyl group; (C₃-C₄)-alkenyl or alkynyl; phenyl optionally substituted with a carboxyl group; naphthyl; COR, SO₃R;

B is OR¹; NHR²;

20 R is (C₁-C₄)-alkyl;

R¹ is H; an ammonium cation; a pharmaceutically acceptable cation of an alkali or alkaline-earth metal or of an organic base; (C₁-C₄)-alkyl, optionally substituted with a hydroxyl or phenoxy group, which can in its turn

25 optionally be substituted with an acetamino group; phenoxy optionally substituted with an acetamino group;

R² is H; (C₂-C₄)-alkanoyl;

- 2 -

X is OH; NH₂; phenyl optionally substituted with one or more fluorine atoms; 4,5dihydro-2-phenyl-3H-benzindol-3-yl; p-aminobenzenesulfonamido; 4-[(pyridinylamino)sulfonyl]phenyl-;

5 Y is H; OH;

and the pharmaceutically acceptable salts and metabolites thereof;

(b) the group of compounds with antiinflammatory activity consisting of tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, tenoxicam, nabumetone, aminopyrine, apazone, phenylbutazone, oxyphenbutazone, antipyrine, nimesulide, sulindac, etodolac, mefenamic acid, sodium meclofenamate, zileuton;

15 and the pharmaceutically acceptable salts and metabolites thereof;

(c) benzoic acid, 2,3-dihydroxy-benzoic acid and sulfanylamide;

20 and the pharmaceutically acceptable salts and metabolites thereof;

for the preparation of a medicament for the prevention and/or the treatment of glutamate receptor-mediated neuronal damages.

Examples of cations deriving from pharmaceutically acceptable organic bases are aliphatic organic amines, such as glucamine, cyclic amines, such as morpholine, heterocyclic amines such as imidazole, and those deriving from amino acids, such as lysine.

The compounds of general formula (I) comprise 30 medicaments having antiinflammatory and/or analgesic and/or antipyretic activities (NSAID) selected from the

- 3 -

group consisting of acetylsalicylic acid (ASA), sodium salicylate (NaSal), salicylamide, salicylamide- Oacetic acid, salacetamide, flufenisal, diflunisal, acetaminosalol, calcium acetylsalicylate, benorylate, fendosal, 5 salicyl-sulfuric acid, etersalate, gentisic acid, glycol salicylate, mesalamine, imidazole salicylate, lysine acetylsalicylate, morpholine salicylate, 1-naphthyl salicylate, parsalimide, phenyl acetylsalicylate, salsalate, sulfasalazine, olsalazine, methyl salicylate, 10 methyl acetylsalicylate.

A preferred embodiment of the present invention provides the use of ASA or of its metabolite, NaSal, for the prevention and/or the treatment of glutamate receptor-mediated neuronal damages.

15 ASA is undoubtedly the most widely employed medicament among NSAIDs, thanks to its very wide pharmacological spectrum which makes ASA suitable, at different dosages, as an analgesic, antinflammatory and antipyretic agent and for limiting the risk of cardiac 20 diseases as well as episodic ischemic syndromes; recently the lower incidence of lung, colon and breast cancer following the repeated administration of ASA has been proved.

The hypothesis that inflammatory processes 25 contribute to the pathology of neurodegenerative diseases, particularly Alzheimer' disease (AD), is supported by clinical and epidemiological studies [P.L. McGeer et al., Lancet 335, 1037 (1990); P.L. McGeer et al., Neurology 42, 447 (1992); J.C.S. Breitner et al., 30 Neurology 44, 227, (1994); J.C.S. Breitner et al., Neurobiol. Aging 16, 523 (1995); J.B. Rich et al;

- 4 -

Neurology 45, 51 (1995); K. Andersen et al., Neurology 45, 1441 (1995)] which indicated that patients administered with antinflammatory medicaments or who were affected by other pathologies for which said medicaments are usually employed, show a lower risk of developing AD.

Moreover, it has been proved [J. Rogers et al. Neurology 43, 1609, (1993)] that another NSAID reduces the progression of cognitive decline in AD patients.

Despite their wide use in several clinical settings, the mechanism underlying the pharmacological properties of non-steroidal antinflammatory drugs has not been completely established. Drug effectiveness has been ascribed to the ability to prevent prostaglandins (PGs) and thromboxanes (TXs) production by inhibiting the enzyme cyclooxygenase (COX) [P. Insel, in Goodman and Gilman's The pharmacological Basis of Therapeutics (McGraw-Hill, New York, 9th ed. pp. 617-657; G. Weismann, Sci. Am., 264, 84 (1991); K.D. Rainsford, in Acetylsalicylic acid and the Salicylates (Butterworths, London, 1984); J.P. Famaey et al., Therapeutic Applications of NSAIDs Subpopulations and New Formulations (Dekker, New York, 1992)].

Nevertheless, some inconsistencies within this hypothesis make the mechanism of action of these drugs still a matter of debate. For instance, salicylic acid lacks inhibitory activity on COX. Moreover, doses of drugs needed to treat chronic inflammatory diseases are consistently higher than those required to inhibit PGs synthesis.

Now it has surprisingly been found, and it is an object of the present invention, that the above non-

- 5 -

steroidal antinflammatory compounds of formula (I) and the pharmaceutically acceptable salts and metabolites thereof have properties making them suitable for the prevention and/or the treatment of glutamate receptor-mediated neuronal damages, independently of any antiinflammatory properties thereof, at concentrations compatible with the plasma levels kept during the treatment of an inflammatory condition such as arthritis.

In fact, said compounds unexpectedly and independently of any antiinflammatory properties thereof show a protective activity against glutamate-induced neurotoxicity.

Glutamate is the most abundant excitatory neurotransmitter in the brain. However, under certain undefined conditions, it may become a potent excitotoxin. Its contribution to the neurodegeneration associated with several acute and chronic neurodegenerative disorders, including AD, is widely established [Lipton et al., New Engl. J. Med. 330, 613-622 (1995); M. Memo et al., Int. Rev. Psych. 7, 339 (1995)].

Several models of neurons in culture have been extensively used to unravel the molecular events triggered by glutamate and leading to cell death as well as to develop a variety of pharmacological compounds able to counteract excitotoxicity. Among them, the primary culture of rat cerebellar granule cells has been selected, where a brief pulse of glutamate, through activation of the glutamate receptor belonging to the N-methyl-D-aspartate (NMDA) subtype, induces cell death [Gallo et al., Proc. Natl. Acad. Sci. USA 79, 7919-7923; M. Favaron et al., Proc. Natl. Acad. Sci. USA 85, 7351

(1988)].

Particularly preferred is the use of acetylsalicylic acid (ASA) and/or of its metabolite, sodium salicylate (NaSal).

5 Also preferred are salicylic acid, salicylamide, salicylamide-O-acetic acid and salacetamide and those ASA and NaSal derivatives having bioavailability characteristics at the brain level.

It has been found that such non-steroidal
10 antiinflammatory compounds are particularly suitable for use in the prevention of glutamate receptor-mediated neuronal damages related to Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, Parkinson' disease, cranial and spinal traumas, multi-
15 infarct dementia, Lewy Body dementia, AIDS-associated dementia, central and peripheral ischemic neuropathies, neuropathies due to anoxic and/or glycemic damages, multiple sclerosis, infective and/or toxic neurodegenerative diseases, neurodegenerative syndromes
20 in prion diseases, ataxias-telangiectasias, epilepsy-related neurodegenerative processes, metabolic neuropathies and other related neuropathologies.

A further object of the present invention is the use of non-steroidal antiinflammatory compounds for the
25 preparation of a medicament for the prevention and/or the treatment of glutamate receptor-mediated neuronal damages.

In order to prove the protective activity of compounds with formula (I) against glutamate
30 neurotoxicity, ASA and NaSal were added to the culture medium 5 min before the addition of glutamate. Glutamate

- 7 -

was used at a 50 μ M concentration, which concentration is capable of reducing cell survival by 70-80 %.

The range of the concentrations used for both drugs is related, as it is shown in the following table, to the
5 plasma levels reached during the antiinflammatory therapy of patients affected with rheumatic diseases.

Table

Relationship between plasma levels maintained during antiinflammatory therapy of humans, neuroprotective effect of the tested compounds and COX inhibition.

Agent	Plasma levels	Tested doses	Hippocampus neuroprotection (EC ₅₀)	Primary neurons neuroprotection (EC ₅₀)	COX inhibition
ASA	1-3 mM	1-3 mM	< 3 mM	1.7 mM	+
NaSal	1-3 mM	2-10 mM	< 2 mM	5 mM	-
indome- thacin	1-20 µM	1-20 µM	ND	NS	+
NaCl		20 mM	ND	NS	
ND: not determinated NS: not sufficient					

As shown in Fig. 1, a dose-dependent protection against glutamate-induced neurotoxicity was observed in the presence of both drugs. For ASA, the calculated value, i.e. the mean effective concentration inducing a 50% effective response (hereinafter referred to as EC₅₀) was 1.7 mM, with a maximum effect (equivalent to 83% protection) exerted at 3 mM. The concentration of NaSal giving 50% of protection was about 5 mM, with a maximal response (87% protection) observed at 10 mM.

10 Unlike salicylates, indomethacin was unable to prevent glutamate-evoked cell death at doses compatible with the plasma levels during drug chronic treatment, (1-20 mM) (Table 1).

Neuroprotection was also evaluated in a different 15 experimental model corresponding to slices of 8 day-old rat hippocampus. This experimental setting offered several advantages compared to primary cultures of neurons, which make it more predictive for an in vivo effect of these drugs. First of all, hippocampus contains 20 the neurons which are the most vulnerable to excitotoxic damage, namely the granular and pyramidal; additionally, the ex vivo preparation represents an heterogeneous population of neurons which have been differentiated in vivo.

25 In agreement with previous findings, stimulation of the NMDA receptor subtype by application of the selective agonist (NMDA, 30 μ M, for 30 min) specifically induced a characteristic cell injury.

Most pyramidal neurons of CA1, CA3 and granule cells 30 of dentate gyrus (DG) exposed to NMDA became acutely necrotic: they exhibited highly swollen cytoplasm

- 10 -

containing large vacuoles, nuclear shrinkage and focal clumping of chromatin.

It has been found that the application of ASA preserved hippocampal cell viability from the NMDA-mediated injury.

The effect of ASA was evaluated at concentrations ranging from 1 to 10 mM. A quantitative analysis of the results is summarized in Fig. 2. In this experimental model ASA did not modify cell viability at 1 mM concentration, while at 3 mM it specifically produced a significant neuroprotection in the CA3 region. Higher concentrations of ASA elicited an almost complete prevention of NMDA effect even in CA1 and DG, besides CA3.

The drug did not modify per se neuron viability.

Interestingly, NaSal already at 2 mM concentrations was capable of efficiently counteracting NMDA-mediated toxicity in hippocampal slices (Fig. 2) compared to what observed in primary cultures of rat cerebellar granule cells.

In the attempt to dissect the molecular mechanisms by which salicylates protect cell viability against glutamate-induced neurotoxicity, the possibility that these drugs might counteract glutamate-evoked cell death by diminishing the NMDA-mediated calcium entry was investigated. [D.W. Choi, J. Neurosci. 7, 369 (1987)]. The hypothesis was tested in primary cultures of rat granule cells by measuring the intracellular calcium concentration by means of microfluorimetry. Application of glutamate in the absence of external Mg^{2+} caused a rapid increase in calcium concentration followed by a

- 11 -

sustained plateau (Fig. 3), mainly due to the NMDA receptor subtype activation.

Cytosolic free calcium concentration was investigated in single cells by microfluorimetric technique using the fluorescent probe "Fura 2" (from Sigma) as described by M. Pizzi et al. in Mol. Pharmacol. 49, 586 (1996). Cells were exposed to glutamate for 2 min in the chamber containing Mg^{2+} -free Krebs-Ringer solution (KRS). ASA and/or NaSal were added to the chamber 2 min before glutamate exposure. Fluorescence image acquisition and analysis were performed by MIRAcAl (Multiple Image Rationing and Analysis with Calibration) system by Applied Imaging (UK).

ASA, applied at neuroprotective concentrations ranging from 1 to 3 mM, induced no changes in cell responsiveness to glutamate. It should be noted that the drug induced per se an exceedingly limited and transient increase in calcium concentration.

A representative experiment performed utilizing 3 mM ASA is depicted in Fig. 3B.

Similarly, NaSal at neuroprotective concentrations ranging from 2 to 10 mM, did not modify cell responsiveness to glutamate, although inducing per se a limited, transient increase in calcium concentration.

These results strongly excluded a possible negative modulatory effect of both ASA and NaSal on the NMDA receptor efficiency and suggested their interference with intracellular molecular targets further downstream glutamate receptor activation in the cascade of events triggering excitotoxicity. To this regard, salicylates appear distinguishable from most drugs endowed with

- 12 -

neuroprotective properties. Moreover, these data indicate that neuroprotection can occur independently of the mechanisms controlling calcium concentration homoeostasis.

5 Administration of glutamate to primary cultures of rat cerebellar granule cells also results in upregulation of the NF- κ B nuclear activity and of the transcriptional complex AP-1 (Fig.4). Cells were exposed to 50 μ M glutamate in the absence or presence of ASA (1,
10 3 mM) and NaSal (3, 10 mM) and nuclear extracts were prepared 1 h after stimulation. Nuclear extracts from rat cerebellar granule cells were subjected to an electrophoretic mobility-shift assay with γ -³²P-labeled oligonucleotide probes containing the immunoglobulin κ B
15 (lanes 1 to 6) and the AP-1 DNA binding sites (lanes 7 to 12). Cells were either unstimulated (lanes 1 and 7) or stimulated with 50 μ M glutamate (15-min pulse) in the absence (lines 2 and 8) or presence (lanes 3 to 6 and 9 to 12) of the drugs as indicated. Both drugs inhibited
20 glutamate-induced increase of NF- κ B activity in a concentration-dependent manner (Fig.4), with calculated EC₅₀ values of 1.3 mM and 6 mM for ASA and NaSal respectively. Parallel experiments in which cell viability was measured at later times (24 h), revealed a
25 strict correlation between neuroprotective concentrations of anti-inflammatory drugs and blockade of NF- κ B induction (EC₅₀ values of 1.5 mM for ASA and 5.8 mM for NaSal). The salicylate effect on NF- κ B/Rel proteins was specific. In fact, ASA and NaSal failed to modify the
30 glutamate-mediated nuclear induction of the transcriptional complex AP-1 (Fig. 4).

Therefore it is ascertained that, at concentrations compatible with plasma levels reached during treatment of chronic inflammatory states, salicylates prevent glutamate-induced neurotoxicity.

5 Interestingly, the site of action common to ASA and NaSal, but not to indomethacin, is the blockade of induction of NF-kB transcription nuclear factors, which is a indisputable prove of the relationship between neuroprotection and cellular event.

10 The results were obtained preparing primary cultures of cerebellar granule cells from cerebella of 8-day-old rats (Sprague-Dawley). The cultures were used at 10-12 days in vitro (DIV), and contained > 95% glutamatergic granule neurons. Neurotoxicity was induced essentially as follows: cells were washed twice with Mg^{2+} -free Locke solution [154 mM NaCl; 5.6 mM KCl; 3.6 mM $NaHCO_3$; 2.3 mM $CaCl_2$; 5.6 mM glucose; 5 mM HEPES (buffer solution base on N-[2-hydroxyethyl]-piperazin-N'-ethanesulfonic acid) free from magnesium ions and afterwards were incubated
15 with 50 μM glutamate in Locke solution free from magnesium ions for 15 minutes (25°C). The glutamate-containing solution was then removed by aspiration and the cells were washed twice with Locke solution containing 1 mM Mg_2SO_4 , then returned to the incubator in
20 their original medium. Cell survival was evaluated after 24 hours, according to the procedure by K.H. Johnes et al. J. Histochem, Cytochem. 33, 77 (1985).
25

Hippocampal slices were obtained from eight-day old Sprague-Dawley rats. Sections were prepared according to
30 what described by J. Gathwaite et al., Neurosci. Lett. 97, 316 (1989). Transverse slices of hippocampus cut at

- 14 -

a thickness of 0.5 mm by a Vibroslice (Campden Instruments LTD, U.K.), were submerged in 2 ml of a Krebs solution containing 11 mM glucose, equilibrated with 95% O₂ - 5% CO₂ (pH 7.4), and preincubated at 37°C for 30 min. After that, 30 µM NMDA was added and incubation was carried out for 30 min. At the end of this period, slices were washed and further incubated in fresh buffer for 90 min in order to allow irreversibly damaged neurons to become visibly necrotic while giving reversibly damaged cells time to recover. Test drugs, ASA and NaSal, were added to slices since the preincubation period. Slices were fixed in a mixture of 4 % paraformaldehyde and 2.5 % glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) then embedded in epoxy resin consisting of glycid ether; 2-dodecenylsuccinic anhydride; methyl nadic anhydride; 2,4,6-tris-(dimethylaminomethyl)phenol; respectively in the following ratios 6 : 3 : 3.5 : 0.25 by volume. Semithin sections were cut in the plane of the hippocampal slices, stained with methylene blue and azur II and examined under light microscopy.

To perform a quantitation of cell loss, adjacent cells were counted in cell layer fields taken from CA1, CA3 and the dorsal blade of dentate gyrus. The considered fields measured $1.5 \times 10^4 \text{ mm}^2$. The percentage of cell survival was calculated by the ratio of living cells to total cell number.

It has therefore been proved that non-steroidal antiinflammatory compounds according to the invention have an unexpected capability of effectively counteracting neurodegenerative conditions, by acting directly at the level of neuronal cells.

- 15 -


It should be noted, with respect to those compounds of the invention defined at point (a), that such a characteristic makes their pharmacological spectrum wider than that of other NSAIDs.

5 Therefore, it is unexpectedly possible to use the compounds of the invention previously defined at point (a) also in patients affected with neurodegenerative diseases associated with glutamate-mediated neuronal damages but not with inflammatory conditions, since said
10 compounds have such double and distinct capability of acting as both antiinflammatory and antidegenerative agents.

CLAIMS

1. The use of non-steroidal antiinflammatory compounds selected from:

- 5 (a) the group of compounds deriving from acetylsalicylic acid of the following formula (I)



wherein:

A is H; (C₁-C₄)-alkyl, optionally substituted with a
 15 carboxyl group; (C₃-C₄)-alkenyl or alkynyl; phenyl
 optionally substituted with a carboxyl group; naphthyl;
 COR, SO₃R;

B is OR¹; NHR²;

R is (C₁-C₄)-alkyl;

20 R¹ is H; an ammonium cation; a pharmaceutically
 acceptable cation of an alkali or alkaline-earth metal or
 of an organic base; (C₁-C₄)-alkyl, optionally substituted
 with a hydroxyl or phenoxy group, which can in its turn
 optionally be substituted with an acetamino group;
 25 phenoxy optionally substituted with an acetamino group;

R² is H; (C₂-C₄)-alkanoyl;

X is OH; NH₂; phenyl optionally substituted with one or
 more fluorine atoms; 4,5-dihydro-2-phenyl-3H-benzindol-3-
 yl; p-aminobenzenesulfonamido; 4-[(pyridinylamino)sulfo-
 30 nyl]phenyl-;

Y is H; OH;

- 17 -

and the pharmaceutically acceptable salts and metabolites thereof;

(b) the group of compounds with antiinflammatory activity consisting of tolmetin, ketorolac, diclofenac, ibuprofene, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, tenoxicam, meloxicam, nabumetone, aminopyrine, apazone, phenylbutazone, oxyphenbutazone, antipyrine, nimesulide, sulindac, etodolac, sodium meclofenamate, zileuton;

and the pharmaceutically acceptable salts and metabolites thereof;

(c) benzoic acid, 2,3-dihydroxy-benzoic acid and sulfanylamide;

and the pharmaceutically acceptable salts and metabolites thereof;

for the preparation of a medicament for the prevention and/or the treatment of glutamate receptor-mediated neuronal damages.

2. The use as claimed in claim 1, wherein said compounds defined sub (a) are selected from the group consisting of: acetylsalicylic acid, sodium salicylate, salicylamide, salicylamide- Oacetic acid, salacetamide, flufenisal, diflunisal, acetaminosalol, calcium acetylsalicylate, benorylate, fendosal, salicyl-sulfuric acid, etersalate, gentisic acid, glycol salicylate, mesalamine, imidazole salicylate, lysine acetylsalicylate, morpholine salicylate, 1-naphthyl salicylate, parsalimide, phenyl acetylsalicylate, salsalate, sulfasalazine, olsalazine, methyl salicylate, methyl acetylsalicylate.

3. The use as claimed in claim 1 or 2, wherein said drugs are acetylsalicylic acid and sodium salicylate.

- 18 -

4. The use as claimed in claims 1 to 3, for the preparation of a medicament for the prevention and/or the treatment of Alzheimer's disease, amyotrophic lateral sclerosis, cranial and spinal traumas, multi-infarct
5 dementia, Lewy Body dementia, AIDS-associated dementia, central and peripheral ischemic neuropathies, neuropathies due to anoxic and/or glycemic damages, multiple sclerosis, infective and/or toxic neurodegenerative diseases, neurodegenerative syndromes
10 in prion diseases, ataxias-telangiectasias, epilepsy-related neurodegenerative processes, metabolic neuropathies and other related neuropathologies.
5. The use as claimed in claims 1 to 3, for the preparation of a medicament for the prevention and/or the
15 treatment of Parkinson's disease.
6. The use as claimed in claims 1 to 3, for the preparation of a medicament for the prevention and/or the treatment of Huntington's disease.
7. A method for the prevention and the treatment of
20 glutamate receptor-mediated neuronal damages in a patient, which method comprises administering said patient with an effective amount of a selected non-steroidal antiinflammatory compound as defined in claim 1.




FIG. 1




FIG. 2




FIG. 3A





FIG. 3B

FIG. 4



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.